Endovia Health Sciences (EDVA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Oct, 2026Executive summary
Supplement corrects a scrivener’s error: the annual-meeting record date is October 2, 2026; the meeting is scheduled for November 20, 2026.
The meeting will be held exclusively by live webcast at 10:00 a.m. Eastern Time, with no in-person attendance.
Voting matters and shareholder proposals
Six matters are on the agenda: elect four directors; ratify the independent auditor; advisory say-on-pay; approve 2025 Plan amendments; approve officer and director RSU grants; and authorize adjournment if needed for further proxy solicitation.
Board of directors and corporate governance
Stockholders will elect four directors to serve until the next annual meeting and until their successors are elected and qualified.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Endovia Health Sciences
- Equity-plan changes target 20% insider ownership, with potentially significant ongoing dilution.EDVA
Proxy filing - Stockholders will vote on director elections, auditor ratification, and major equity plan changes.EDVA
Proxy filing - Shareholders will vote on director elections, auditor ratification, and major equity plan changes.EDVA
Proxy filing - Strategic pivot to cannabinoid health sciences amid financial distress and high dilution risk.EDVA
Registration filing - Losses narrowed 64% as the company pivots to cannabinoid health sciences and rebrands.EDVA
Q2 2026 - Pivoting to cannabinoid wellness, company seeks capital via equity line amid financial distress.EDVA
Registration filing - Facing liquidity issues, the company pursues a dilutive equity line and entry into the cannabinoid sector.EDVA
Registration filing - Severe revenue decline, liquidity risk, and pending Medterra deal threaten NYSE listing.EDVA
Q1 2026 - Paused operations, major losses, and a planned Medterra CBD acquisition amid severe liquidity risk.EDVA
Q4 2025